Over the past 15 years, three new classes of drugs, glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl peptidase 4 (DPP-4) inhibitors and sodium glucose cotransporter-2 (SGLT-2) inhibitors have been approved to treat type 2 diabetes based on effects on glycemic control.
Over the past 15 years, three new classes of drugs, glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl peptidase 4 (DPP-4) inhibitors and sodium glucose cotransporter-2 (SGLT- 2) inhibitors have been approved to treat type 2 diabetes based on effects on glycemic control.
Although large randomized controlled trials have played an important role in characterizing the efficacy and safety of these agents on a population level, questions remain about how best to individualize therapy and target the "right" medicine to the "right" patient. In contrast, few medicines have been approved to treat diabetic kidney disease and initiatives have been launched on both sides of the Atlantic to facilitate the development of effective personalized medicines for the treatment of diabetic kidney disease. Increasingly, "omics," imaging and other biomarkers will be used to match patients with therapies to which they are likely to respond best. This review addresses regulatory considerations related to precision medicine, draws lessons learned from other therapeutic areas and discusses efforts undertaken by the European (EMA) and United States (FDA) to facilitate the development of such therapies. Moving forward, an integrated approach that makes use of predictive preclinical models, innovative trial designs, observational "real-world" data and novel statistical methodologies will likely be needed to complement inherently smaller RCTs conducted in more selected populations. Patient involvement will also be critical. Regulatory agencies are ready to engage in such approaches. This landscape, which arguably includes both extremes-a relative abundance of medicines approved to improve glycemic control in type 2 diabetes and questions related to how to choose from among them, as well as a paucity of medicines approved to slow the progression of diabetic kidney disease-highlights the need for more targeted or personalized treatment approaches to maximize the benefit-to-harm ratio of approved therapies and to facilitate the development of new ones.
Such an approach reflects an approach that is increasing being adopted in other areas of medicine, in particular oncology. This review addresses regulatory considerations related to precision medicine, draws lessons learned from other therapeutic areas, and discusses efforts undertaken by the EMA and FDA to facilitate the development of such therapies.
| PRECISION MEDICINE AND THE REGULATORY SYSTEM
Today's regulatory systems aim to ensure the quality and effectiveness/ efficacy of medicines and a positive benefit-risk profile. While the quality of the medicine is essentially the summed assessment of critical product features (eg, potency, product stability, purity), the benefit-risk There are, however, many methodological challenges associated with determining the best patient-therapy match; we discuss some of these challenges in the next section.
| NEW CLINICAL TRIAL DESIGNS FOR PRECISION MEDICINE IN REGULATORY CONTEXT
Regulators are well-versed in evaluating drug effects at a population level based on randomized (double-blind) controlled trials (RCT).
Robust findings in well-conducted RCTs allow regulators to draw conclusions about a drug's benefit-to-harm ratio with reasonable certainty for a population similar to the one studied in the trial. Typically, a drug is approved based on a finding in the overall population, for example, by demonstrating that in the trial population the mean effect in the test arm of the trial is larger than in the placebo arm or at least noninferior to an active control arm, and if adverse effects do not off-set the observed benefit.
In contrast to this population-based approach, precision medicine makes use of an increased understanding of disease biology to a priori define patient groups that are more likely to respond positively or negatively to a treatment; that is, improve the patient-therapy match.
Predictive biomarkers are used to individualize treatment to patients with a specific disease expression or initial treatment response. 12 To date, this approach has been most widely used in oncology with therapies targeted to, and defined by genetic mutations, for example,
Human Epithelial Growth Factor Receptor 1 (HER1) mutations (trastuzumab), 13 programmed death ligand-1 (PDL-1) expression (pembrolizumab) 14 and BRAF mutations (vemurafenib). 15 In the majority of these oncology development programs, translational research and exploratory clinical trials informed the pivotal registration studies.
In other fields, dynamic or response biomarkers thought to predict the long-term benefit or harms of treatment are being explored to target medicines to populations more likely to derive benefit. For example, in the SONAR trial, patients with diabetic kidney disease were randomized to continued active therapy or placebo if they showed a response in albuminuria (>30% decrease) to an initial 6 weeks of atrasentan treatment; some patients who were biomarker "negative" were also enrolled for reasons discussed below. 16 Such dynamic or response biomarkers are needed to individualize treatment. 17 While focusing clinical trial enrollment on patients more likely to respond positively to treatment has obvious advantages, often it is unclear how well the predictive or response biomarker performs in identifying this population, and hence, regulators are often interested in treatment effects in patients who are biomarker negative. Do patients without a certain biomarker response truly not benefit in terms of (long-term) clinical endpoints? Is there really no treatment response in the biomarker negative population? Moreover, rarely does a biomarker fully discriminate between responder and non-responder patients. In other words, the sensitivity and specificity of the biomarker is seldom 100%. Hence, unless there are compelling data or strong scientific rationale for concluding that biomarker negative patients are unlikely to respond to a treatment, regulators encourage the inclusion of marker-negative patients in the trial; the size/proportion of the population included in the trial depends on the level of certainty in the performance of the biomarker or proposed cut-off in identifying responders. In the SONAR trial in patients with diabetic kidney disease, this issue was addressed by including more than 1000 patients with less than a 30% reduction in albuminuria; that is, hypothesized non-responders. Randomization was also stratified according to prespecified albuminuria response strata, with the objective of identifying a minimum albuminuria response threshold associated with a beneficial effect of treatment. caveat though, that is that these enrichment designs may be noninformative on the biomarker-negative population. 20 As described elsewhere in this issue of the Journal, platform, basket and umbrella trials may offer additional innovative study designs for evidence generation in the setting of precision-medicine. 21 In addition, observational "realworld" data may be increasingly considered to provide further evidence postapproval. 22 Finally, multiple smaller trials with clearly defined patient populations could be used to test specific treatments or combinations at various dose levels more appropriately than performing subgroup analyses in large clinical trials. Ideally, these trials would use a standardized data collection that allows future meta-analytical approaches to answer questions that are relevant to a more general population, provided a willingness to share data among different parties. 23 Regulatory experience remains, however, limited and there are many methodological challenges for which regulators, industry, and academic methodologists will need to collaborate in finding solutions.
Clearly, as Eichler and Sweeney write "…the randomised controlled trial must adapt and evolve to respond to a changing environment…." Disease-specific meetings and research consortia also provide an opportunity for regulators from around the world to meet and interact with the larger community on issues related to the development of more targeted therapies. 
